Twice a year, the Research Mobility Fellowships of the European Joint Programme on Rare Diseases (EJP RD) from the European Reference Networks (ERN) get awarded to prominent researchers or MDs to develop new skills and expertise in a European institution specialized in research on rare diseases.
Eva Coopmans, medical doctor and postdoctoral researcher at the Centre of Endocrine Tumors Leiden (Centrum voor Endocriene Tumoren Leiden), supervised by Prof. A.M. Pereira Arias and Prof. N.R. Biermasz, has been awarded the EJP RD – ERN fellowship for a pilot study ‘GH-secreting pituitary tumours: nip therapy resistance in the bud’. This fellowship will allow her to research the role of AIP and GNAS mutations in treatments with somatostatin analogues in vivo at the William Harvey Research Institute (WHRI), Queen Mary University of London (QMUL), under supervision of Prof. Korbonits, one of the world’s leading figures in the area of rare hereditary pituitary gland tumors.
Oana Danila is an endocrinologist in training from the National Institute for Endocrinology, C.I. Parhon, in Bucharest, Romania. She was awarded the EJP RD – ERN fellowship for a case control study called ‘The influence of Growth Hormone excess secretion on the evolution of Fibrous Dysplasia in patients with McCune Albright Syndrome’. This fellowships will enable her to research the role of growth hormone secretion in fibrous dysplasia in patients suffering from McCune Albright syndrome. She will also be able to gain clinical experience with this cohort in the LUMC under the supervision of Dr. Appelman-Dijkstra, one of the leading experts in metabolic bone diseases.
For more information on the EJP RD Research Mobility Fellowships and financing possibilities, please check: https://www.ejprarediseases.org/our-actions-and-services/funding-opportunities/funded-projects/ern-trainings-2/
The EJP RD initiative received financial support from the European Union’s Horizon 2020 research and innovation programme, grant agreement N˚825575. The LUMC/Endo-ERN is partner of the EJP RD.
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
For many students from the LUMC’s academic programmes, studying abroad is an indispensable experience. Doing part of your studies abroad is a special experience, not only because of the sense of adventure of being abroad, also to develop a broader perspective on Life Sciences & Health, a highly international field. So, you can imagine the LUMC’s International Office’s struggle to have to tell students ‘no’ for a study experience abroad in the midst of the corona pandemic. In addition, the many lockdowns worldwide increased the workload dramatically for the International Office. Evelien Hack, Head of the International Office and Sandra van Deursen, senior administrative assistant, share how corona has impacted studying abroad.
The Leiden University Medical Center (LUMC) and Ixaka Ltd. have announced a research collaboration on 30 March 2021, to better understand REX-001, Ixaka’s lead cell therapy product. The project will be led by Professor Paul Quax, Head of Experimental Vascular Surgery at the LUMC, to support accelerated development of REX-001 in Phase III clinical trials for the treatment of chronic limb-threatening ischemia (CLTI).